RevoluGen: John Chisholm

May 05, 2020

RevoluGen has appointed John Chisholm as non-executive chairman. Chisholm was most recently executive chairman of Genomics England where he oversaw the 100,000 Genome Project. RevoluGen said that Chisholm will lend his expertise to the development of the company's business including optimizing applications for its Fire Monkey/Fire Flower high-molecular-weight DNA sample prep products.

Breaking News

FDA Grants Marketing Authorization for Invitae Hereditary Cancer DNA Sequencing Test
Compact Gene Editing Enzyme May Improve Success Rates of Gene Therapies
People in the News at Veracyte, Invitae, Mount Sinai, InterVenn Biosciences, Applied BioCode, More
New Products Posted to GenomeWeb: Qiagen, IDT, Revvity, Mission Bio, NRichDx, More
FDA Releases Proposed Rule for Oversight of Laboratory-Developed Tests

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.